GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » ROC (Joel Greenblatt) %

ESLA (Estrella Immunopharma) ROC (Joel Greenblatt) % : -469.84% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Estrella Immunopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -469.84%.

The historical rank and industry rank for Estrella Immunopharma's ROC (Joel Greenblatt) % or its related term are showing as below:

ESLA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -434.6   Med: 0   Max: 0
Current: -434.6

ESLA's ROC (Joel Greenblatt) % is ranked worse than
55.2% of 1422 companies
in the Biotechnology industry
Industry Median: -318.69 vs ESLA: -434.60

Estrella Immunopharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Estrella Immunopharma ROC (Joel Greenblatt) % Historical Data

The historical data trend for Estrella Immunopharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma ROC (Joel Greenblatt) % Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
ROC (Joel Greenblatt) %
- - - -

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -204,200.00 -111.77 -469.84

Competitive Comparison of Estrella Immunopharma's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Estrella Immunopharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's ROC (Joel Greenblatt) % falls into.



Estrella Immunopharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.5) - (0.138 + 0 + 0)
=3.362

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.181 + 0 + 0)
=-0.181

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Estrella Immunopharma for the quarter that ended in Jun. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-15.796/( ( (0 + max(3.362, 0)) + (0 + max(-0.181, 0)) )/ 1 )
=-15.796/( ( 3.362 + 0 )/ 1 )
=-15.796/3.362
=-469.84 %

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Estrella Immunopharma  (NAS:ESLA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Estrella Immunopharma ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma Headlines